| LAG3 |
IMP321 |
– |
NCT00351949 |
1 |
Metastatic renal cell carcinoma |
|
|
– |
NCT03252938 |
1 |
Advanced solid malignancies |
|
|
Paclitaxel |
NCT00349934 |
1 |
Metastatic breast cancer |
|
|
Paclitaxel |
NCT02614833 |
2 |
Metastatic breast cancer |
|
|
Anti-PD-1 |
NCT02676869 |
1 |
Advanced melanoma |
|
|
Or urelumab (anti-CD137) +/− anti-PD-1 |
NCT02658981 |
1 |
Recurrent glioblastoma |
|
LAG525 |
Anti-PD-1 |
NCT02460224 |
1–2 |
Advanced solid malignancies |
|
BMS986016 |
Anti-PD-1 |
NCT01968109 |
1–2 |
Advanced solid and hematologic malignancies |
|
|
Anti-PD-1 |
NCT02061761 |
1–2 |
Hematologic malignancies |
|
|
Anti PD-1 |
NCT02060188 |
2 |
Colorectal cancer |
|
|
Anti-PD-1 |
NCT02488759 |
1–2 |
Virus-associated tumors |
|
|
Anti-PD-1 |
NCT02935634 |
2 |
Advanced gastric cancer |
|
|
Anti-PD-1 |
NCT02750514 |
2 |
Advanced NSCLC |
|
|
Anti-PD-1 |
NCT02996110 |
2 |
Advanced RCC |
|
|
Anti-PD-1 |
NCT02658981 |
1 |
Recurrent brain neoplasms |
|
|
Anti-PD-1 |
NCT02966548 |
1 |
Advanced solid malignancies |
|
REGN3767 |
Anti-PD-1 |
NCT03005782 |
1 |
Advanced malignancies without any available therapy and immune checkpoint naive |
|
TSR-033 |
+/− Anti-PD-1 |
NCT03250832 |
1 |
Advanced solid malignancies |
|
MGD013 |
– |
NCT03219268 |
1 |
Advanced solid malignancies |
| TIM-3 |
TSR-022 |
Anti-PD-1 |
NCT02817633 |
1 |
Advanced solid malignancies |
|
LY3321367 |
Anti-PD-L1 |
NCT03099109 |
1 |
Advanced solid malignancies |
|
MBG453 |
Anti-PD-1 |
NCT02608268 |
1–2 |
Advanced solid malignancies |
|
|
Anti-PD-1 |
NCT03066648 |
1 |
Acute myeloid leukemia or high-risk myelodysplastic syndrome |
| TIGIT |
OMP-313M32 |
– |
NCT03119428 |
1 |
Advanced solid malignancies |
|
MTIG7192A/RG6058 |
Anti-PD-L1 |
NCT02794571 |
1 |
Advanced solid malignancies |
| VISTA |
JNJ-610588 |
– |
NCT02671955 |
1 |
Advanced solid malignancies |
|
CA-170 |
– |
NCT02812875 |
1 |
Advanced solid and hematologic malignancies |
